Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials
The partnership connects patients using Sequence Me Now's self-advocacy resources with Massive Bio's AI-powered clinical trial matching, giving patients a clear path from genomic testing to treatment options.
Massive Bio, a technology company that uses artificial intelligence to help cancer patients identify clinical trials for which they may be eligible, today announced a new partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization dedicated to helping cancer patients access genomic sequencing and personalized medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713305414/en/
Through the partnership, Massive Bio is featured on the "Find a Trial" page of Sequence Me Now's website, the fourth step of the nonprofit's Sequence Code, a five-step patient playbook founded by Bryce Olson, a cancer patient who used his own genomic sequencing results to outlast an initial 21-month prognosis by nine years. Massive Bio, in turn, has built a dedicated landing page for Sequence Me Now patients, where they can complete an intake form to explore what clinical trials may be available to them based on their diagnosis and biomarker profile.
